NeuroMab™ Anti-Tau; pTau BBB Shuttle Antibody(NRZP-1022-ZP3099)

Figure 1 shows the specificity of tau antibodies raised against the tau peptide p391-409, as determined by immunoblotting of recombinant tau protein phosphorylated in vitro by p42 MAPK or GSK3β.

Figure 2 shows the characterization of the specificity of the tau antibody by immunoblot analysis using whole brain lysates from nTg, tau KO, and PS19 tau Tg mice using actin as a control.

Figure 3 shows immunocytochemistry of representative tau pathology in human AD brain and JNPL3 Tg mice with antibodies PHF17 and PHF20.

Immuno-reactivity of previously characterized phospho-tau antibodies PHF1 and new tau antibodies PHF17 or PHF20 in the hippocampus of a control subject or a subject with AD, and in the spinal cord of 12 month old nTg and JNPL3 Tg mice. Arrows indicate NFTs in human brain or NFT-like inclusion pathology in JNPL3 mice. Asterisks depict dystrophic neurites within senile plaques. Bar=100 μm, and 200 μm for insets.

Figure 4 shows the biochemical characterization of sarcosyl-insoluble tau detected by a tau antibody in human brain lysates from AD patients.